Spots Global Cancer Trial Database for SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Official Title: A Phase 1 Study of SG301 in Subjects With Hematological Malignancies
Study ID: NCT04684108
Interventions
Study Description
Brief Summary: This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Detailed Description: After a screening period of up to 28 days for each study phase, qualified patients will be enrolled to receive their assigned dose of SG301, administered weekly for the first 2 cycles and every 2 weeks thereafter, until disease progression or intolerable toxicity, starting of a new anticancer treatment, withdrawal of consent, lost to follow up, death, or end of the study, whichever occurs first. The study consists of a dose escalation phase (Phase 1a) and a dose expansion phase (Phase 1b) in subjects with relapsed or refractory multiple myeloma and other hematological malignancies.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing, China
Beijing Jishuitan Hostipal, Beijing, Beijing, China
Shenzhen Second People's Hospital, Shenzhen, Guangzhou, China
The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Wuhan University Central South Hospital, Wuhan, Hubei, China
Xiangyang Central Hospital, Xiangyang, Hubei, China
Wuxi Central Hospital, Wuxi, Jiangsu, China
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Shanxi Norman Bethune Hospital, Taiyuan, Shanxi, China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
